What is the average price of velpatasvir exports from India?

The average unit price for velpatasvir exports from India is $88.44 USD per unit, with prices ranging from $0.94 to $6479.33 depending on formulation, packaging, and order volume. The total market is valued at $24.7M across 671 shipments.

Which ports handle velpatasvir exports from India?

The primary ports for velpatasvir exports from India are SAHAR AIR CARGO ACC (INBOM4) (22.5% of shipments), SAHAR AIR (20.9% of shipments), DELHI AIR CARGO ACC (INDEL4) (10.6% of shipments), Bombay Air (9.2% of shipments), DELHI AIR (7.5% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of velpatasvir?

India is one of the world's leading exporters of velpatasvir due to its large base of 103 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports velpatasvir to 95 countries, demonstrating 49% global market coverage.

What certifications do Indian velpatasvir exporters need?

Indian velpatasvir exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import velpatasvir from India?

There are 235 registered buyers importing velpatasvir from India, spread across 95 countries. The repeat buyer rate is 43.0%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top velpatasvir supplier from India?

MYLAN LABORATORIES LIMITED is the leading velpatasvir exporter from India with a market share of 49.6% and total export value of $12.2M across 63 shipments. The top 5 suppliers together control 92.8% of total export value.

Velpatasvir

India Pharmaceutical Trade Intelligence

$24.7M103 Suppliers95 CountriesHS 30049099

ExportsIndia → VIETNAM19.1%India → LATVIA14.9%

ImportsUNITED STATES → India$206.1K GERMANY → India$43.1K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: SIA "MAGNIPHARMA",

Velpatasvir Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Velpatasvir to the World

Q: Who are the top velpatasvir exporters from India?

The top velpatasvir exporters from India are: 1. MYLAN LABORATORIES LIMITED — $12.2M (49.6% market share); 2. HETERO LABS LIMITED — $5.2M (21.0% market share); 3. EURO LIFECARE PRIVATE LIMITED — $3.9M (15.7% market share); 4. NATCO PHARMA LIMITED — $1.3M (5.2% market share); 5. KARDI TRADING PRIVATE LIMITED — $311.7K (1.3% market share). Together they account for 92.8% of India's total velpatasvir export value.

Q: What is the total export value of velpatasvir from India?

The total export value of velpatasvir from India is $24.7M USD, recorded across 671 shipment transactions from 103 active exporters to 95 destination countries. The average shipment value is $36.7K.

Q: Which countries import velpatasvir from India?

India exports velpatasvir to 95 countries worldwide. The top importing countries are: VIETNAM (19.1% share, $4.7M), LATVIA (14.9% share, $3.7M), POLAND (14.1% share, $3.5M), KYRGYZSTAN (5.9% share, $1.5M), AZERBAIJAN (5.2% share, $1.3M). These five markets account for 59.2% of total export value.

Q: What is the HS code for velpatasvir exports from India?

The primary HS code for velpatasvir exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Between 2022 and 2026, India exported $24.7M worth of velpatasvir across 671 verified shipments to 95 countries — covering 49% of world markets in the Antiviral & HIV Medications segment. The largest destination is VIETNAM (19.1%). MYLAN LABORATORIES LIMITED leads with a 49.6% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Velpatasvir export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Velpatasvir export data snapshot — $24.7M · 103 exporters · 95 countriesTransData Nexus · Indian Customs Data

Top Velpatasvir Exporters from India

103 active exporters · Ranked by export value

View all 103 →

Top Velpatasvir Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	MYLAN LABORATORIES LIMITED	$12.2M	63	23	49.6%
2	HETERO LABS LIMITED

Top Countries Importing Velpatasvir from India

95 destination markets · Ranked by import value

All 95 countries →

Top Countries Importing Velpatasvir from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	VIETNAM	$4.7M	19.1%
2	LATVIA	$3.7M	14.9%
3	POLAND	$3.5M	14.1%
4	KYRGYZSTAN	$1.5M	5.9%
5	AZERBAIJAN	$1.3M	5.2%
6	GEORGIA	$1.2M	4.8%
7	NEPAL	$974.4K	4.0%
8	KAZAKHSTAN	$900.4K	3.7%
9	THAILAND	$760.5K	3.1%
10	MYANMAR	$668.9K	2.7%

VIETNAM is India's largest velpatasvir export destination, absorbing 19.1% of total exports worth $4.7M. The top 5 importing countries — VIETNAM, LATVIA, POLAND, KYRGYZSTAN, AZERBAIJAN — together account for 59.2% of India's total velpatasvir export value. The remaining 90 destination countries collectively receive the other 40.8%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Velpatasvir to India?

4 origin countries · Total import value: $279.2K

India imports velpatasvir from 4 countries with a combined import value of $279.2K. The largest supplier is UNITED STATES ($206.1K, 3 shipments), followed by GERMANY and UNITED ARAB EMIRATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Velpatasvir to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$206.1K	3	73.8%
2	GERMANY	$43.1K	2	15.4%
3	UNITED ARAB EMIRATES	$29.9K	1	10.7%
4	PHILIPPINES	$129	1	0.0%

UNITED STATES is the largest supplier of velpatasvir to India, accounting for 73.8% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Velpatasvir

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for the combination of sofosbuvir and velpatasvir, indicating a competitive generic market. The most recent approval was granted in January 2026. There are no current import alerts related to velpatasvir, suggesting compliance with FDA standards. The regulatory pathway for velpatasvir involves demonstrating bioequivalence to the reference listed drug, Epclusa, and adherence to Current Good Manufacturing Practices (CGMP). Given the presence of 103 active Indian exporters, it is imperative for each to maintain stringent quality controls to meet FDA requirements.

2EU & UK Regulatory Framework

The European Medicines Agency (EMA) granted marketing authorization for the sofosbuvir/velpatasvir combination under the brand name Epclusa in July 2016. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has similarly approved this combination. Manufacturers exporting to these markets must comply with EU Good Manufacturing Practice (GMP) guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, quality control, and self-inspection. Adherence to these standards is crucial for market access and sustained presence in the EU and UK.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) included the sofosbuvir/velpatasvir combination in its Model List of Essential Medicines in June 2017, recognizing its efficacy across all HCV genotypes. Additionally, the WHO Prequalification Programme has prequalified velpatasvir, with Matrix Pharmacorp Private Limited's product achieving this status in December 2020. Velpatasvir is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality benchmarks globally.

4India Regulatory Classification

In India, velpatasvir is classified under Schedule H, indicating it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), has not set a ceiling price for velpatasvir as of March 2026. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the export of pharmaceutical products.

5Patent & Exclusivity Status

The primary patents for the sofosbuvir/velpatasvir combination, marketed as Epclusa by Gilead Sciences, are set to expire between 2028 and 2034. This timeline suggests a gradual increase in generic competition, particularly in markets where patent protections have lapsed or compulsory licenses have been issued. Indian exporters should monitor these developments to strategically position themselves in the global market.

6Recent Industry Developments

In April 2025, the WHO updated its Essential Medicines List, reaffirming the inclusion of the sofosbuvir/velpatasvir combination, underscoring its continued importance in HCV treatment protocols. In June 2025, the EMA approved a new generic version of the sofosbuvir/velpatasvir combination, enhancing market competition within the EU. In September 2025, the NPPA conducted a review of antiviral drug prices, including velpatasvir, to assess affordability and accessibility, though no price ceiling was imposed. In November 2025, the FDA issued updated guidance on the manufacturing of direct-acting antivirals, emphasizing the need for stringent quality controls, which is pertinent for Indian exporters targeting the US market. In January 2026, the CDSCO introduced a streamlined process for the export NOC of HCV medications, aiming to facilitate faster approvals for compliant manufacturers.

These developments highlight the dynamic regulatory landscape surrounding velpatasvir, necessitating continuous vigilance and adaptability from Indian exporters to maintain and expand their global market presence.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Velpatasvir

Retail & reference prices across 9 markets vs. India FOB export price of $88.44/unit

Global Price Benchmark for Velpatasvir across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	N/A	USD	Specific pricing information for Velpatasvir in the United States is not publicly disclosed by government agencies.
United Kingdom	N/A	GBP	The National Health Service (NHS) Drug Tariff does not publicly list the price for the Sofosbuvir/Velpatasvir combination.
Germany	N/A	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) does not publicly disclose pricing information for this medication.
Australia	N/A

Supply Chain Risk Assessment — Velpatasvir

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs), the essential chemical precursors for Active Pharmaceutical Ingredients (APIs). Approximately 60–70% of KSMs used in Indian API production are imported from China. This dependency poses a significant risk, as any disruption in Chinese supply chains can directly impact India's pharmaceutical manufacturing capabilities. For instance, in September 2025, China reduced the prices of 41 APIs and KSMs by 40–50%, affecting the competitiveness of Indian API manufacturers.

Despite efforts to reduce reliance on Chinese imports, such as the inauguration of two greenfield plants under the Production Linked Incentive (PLI) scheme in November 2024, India's dependence on China for critical pharmaceutical ingredients remains substantial. These plants aim to produce essential molecules like Penicillin G and Clavulanic Acid, but the overall impact on reducing import dependence is yet to be fully realized.

2Supplier Concentration & Single-Source Risk

The Velpatasvir export market is highly concentrated, with the top five exporters accounting for 92.8% of total exports. MYLAN LABORATORIES LIMITED alone holds a 49.6% share. Such concentration increases the risk of supply disruptions, as any operational issues within these key companies could significantly impact the global supply of Velpatasvir. While the PLI scheme has encouraged domestic production of APIs and KSMs, the effectiveness of these initiatives in diversifying the supplier base and mitigating single-source risks is still under evaluation.

Access Complete Velpatasvir Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 671 transactions across 95 markets.

Request Demo View Pricing

Frequently Asked Questions — Velpatasvir Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top velpatasvir exporters from India?

The leading velpatasvir exporters from India are MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED, EURO LIFECARE PRIVATE LIMITED, and 8 others. MYLAN LABORATORIES LIMITED leads with 49.6% market share ($12.2M). The top 5 suppliers together control 92.8% of total export value.

What is the total export value of velpatasvir from India?

The total export value of velpatasvir from India is $24.7M, recorded across 671 shipments from 103 active exporters to 95 countries. The average shipment value is $36.7K.

Which countries import velpatasvir from India?

India exports velpatasvir to 95 countries. The top importing countries are VIETNAM (19.1%), LATVIA (14.9%), POLAND (14.1%), KYRGYZSTAN (5.9%), AZERBAIJAN (5.2%), which together account for 59.2% of total export value.

What is the HS code for velpatasvir exports from India?

The primary HS code for velpatasvir exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Velpatasvir

Velpatasvir

Top Velpatasvir Exporters from India

Top Countries Importing Velpatasvir from India

Who Supplies Velpatasvir to India?

Quick Facts

Related Antiviral & HIV Medications

Related Analysis

Need Details?

Regulatory Landscape — Velpatasvir

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Velpatasvir

Supply Chain Risk Assessment — Velpatasvir

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Velpatasvir Trade Intelligence

Frequently Asked Questions — Velpatasvir Exports from India

Who are the top velpatasvir exporters from India?

What is the total export value of velpatasvir from India?

Which countries import velpatasvir from India?

What is the HS code for velpatasvir exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of velpatasvir exports from India?

Which ports handle velpatasvir exports from India?

Why is India a leading exporter of velpatasvir?

What certifications do Indian velpatasvir exporters need?

How many buyers import velpatasvir from India?

What is the market share of the top velpatasvir exporter from India?

Analysis Methodology